- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.04. | SIRNAOMICS-B (02257): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2023 | 1 | HKEx | ||
| 29.04. | SIRNAOMICS-B (02257): ANNUAL REPORT 2023 | 1 | HKEx | ||
| 17.04. | SIRNAOMICS-B Once Surges 38%; Group Receives Specific Guidance from US FDA for Treatment of isSCC | 1 | AASTOCKS | ||
| 16.04. | SIRNAOMICS-B (02257): VOLUNTARY ANNOUNCEMENT - SIRNAOMICS RECEIVED FDA SPECIFIC GUIDANCE FOR FURTHER DEVELOPMENT OF STP705 FOR TREATMENT OF SQUAMOUS CELL ... | 1 | HKEx | ||
| 28.03. | Sirnaomics Announces 2023 Annual Results | 209 | PR Newswire | Focuses on the Consolidation for Leading Projects
Accelerates Clinical Trials for Core Products STP705, STP707 and STP122G
HONG KONG, Germantown, Md. and SUZHOU, China, March 28, 2024 /PRNewswire/... ► Artikel lesen | |
| 27.03. | SIRNAOMICS-B (02257): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 | 1 | HKEx | ||
| 13.03. | SIRNAOMICS-B (02257): NOTICE OF BOARD MEETING | 1 | HKEx | ||
| 07.03. | SIRNAOMICS-B (02257): ANNOUNCEMENT IN RELATION TO DEALINGS IN SECURITIES OF A DIRECTOR DURING THE BLACK-OUT PERIOD | - | HKEx | ||
| 29.02. | SIRNAOMICS-B (02257): VOLUNTARY ANNOUNCEMENT - UNUSUAL SHARE PRICE MOVEMENT | 1 | HKEx | ||
| 30.01. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 30.01.2024 | 421 | Xetra Newsboard | The following instruments on XETRA do have their first trading 30.01.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 30.01.2024
Aktien
1 ZAE000314084 OUTsurance Group Ltd.
2... ► Artikel lesen | |
| 24.01. | Sirnaomics Publishes Novel Mechanism of Action of RNAi Cancer Therapeutic STP707 for Solid Tumors | 258 | PR Newswire | Study published in NAR Cancer, a leading peer-reviewed journal in the field of nucleic acid therapeutics
HONG KONG, Germantown, Md. and SUZHOU, China, Jan. 24, 2024 /PRNewswire/ -- Sirnaomics Ltd.... ► Artikel lesen | |
| 18.12.23 | SIRNAOMICS-B (02257): VOLUNTARY ANNOUNCEMENT - RNAIMMUNE RECEIVES INVESTIGATIONAL NEW DRUG APPLICATION CLEARANCE FROM U.S. FDA FOR MRNA-BASED RESPIRATORY ... | 1 | HKEx | ||
| 06.12.23 | SIRNAOMICS-B (02257): CONNECTED TRANSACTION - GRANT OF STOCK OPTIONS BY A SUBSIDIARY TO A CONNECTED PERSON | 2 | HKEx | ||
| 05.12.23 | SIRNAOMICS-B (02257): VOLUNTARY ANNOUNCEMENT - SIRNAOMICS ANNOUNCES SUCCESSFUL COMPLETION OF COHORT 1 FROM PHASE I CLINICAL STUDY OF GALNAC-BASED RNAI ... | 2 | HKEx | ||
| 01.12.23 | Sirnaomics Names Francois Lebel Chief Medical Officer | 2 | Contract Pharma | ||
| 30.11.23 | SIRNAOMICS-B (02257): GRANT OF SHARE OPTIONS | 1 | HKEx | ||
| 30.11.23 | SIRNAOMICS-B (02257): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 30.11.23 | SIRNAOMICS-B (02257): RESIGNATION OF EXECUTIVE DIRECTOR AND CHANGES TO SENIOR MANAGEMENT | - | HKEx | ||
| 31.08.23 | Sirnaomics Announces 2023 Interim Results | 358 | PR Newswire | Positive Clinical Readouts Validate Potential of Proprietary Delivery Platforms and Cement Global Leadership in RNAi Therapeutics
Business Highlights
Promising progress in clinical development
After... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,940 | +0,90 % | Qiagen zuletzt sehr stark. Der Montag wird wahnsinnig wichtig! | Grund zum Feiern haben heute alle Qiagen-Aktionäre. Schließlich errechnet sich im Vergleich zur Vorwoche ein Zugewinn von 2,87 Prozent. Das Wertpapier verabschiedete sich an vier der vier Sitzungen... ► Artikel lesen | |
| EVOTEC | 9,760 | -1,36 % | Starke Börsenwoche für Evotec. DAS ist jetzt wichtig. | Bei Evotec feierten in der vergangenen Woche die Bullen. Immerhin gewann der Kurs im Vergleich zum Vorwochenschluss rund 4,89 Prozent. An drei der vier Sitzungen ging das Wertpapier mit Aufschlägen... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 45,110 | +4,06 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates | - Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter - - Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 37,400 | +3,03 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update | KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2)... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 8,000 | -6,98 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in... ► Artikel lesen | |
| DYNE THERAPEUTICS | 26,080 | +0,31 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights | - Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 - WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,840 | +0,57 % | (RXRX) - Analyzing Recursion Pharmaceuticals' Short Interest | ||
| NUVALENT | 70,35 | -2,95 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen | |
| CG ONCOLOGY | 36,270 | -8,18 % | CG Oncology Inc.: Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | - Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today... ► Artikel lesen | |
| JANUX THERAPEUTICS | 64,78 | +3,76 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
| ANNEXON | 4,880 | +4,72 % | Annexon (ANNX) to Report Q1 Earnings: What's in the Cards? | ||
| SANA BIOTECHNOLOGY | 10,440 | +6,75 % | Sana Biotechnology, Inc: Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates | Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in relapsed/refractory... ► Artikel lesen | |
| CABALETTA BIO | 12,390 | -1,67 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 27,270 | +2,83 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 26,450 | +3,40 % | Navigating 7 Analyst Ratings For Avidity Biosciences |
Das Unternehmen SIRNAOMICS LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,594 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
